Atea Pharmaceuticals (AVIR)
(Delayed Data from NSDQ)
$3.52 USD
+0.10 (2.92%)
Updated Jan 3, 2025 04:00 PM ET
After-Market: $3.51 -0.01 (-0.28%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth D Momentum D VGM
Price, Consensus and EPS Surprise
AVIR 3.52 +0.10(2.92%)
Will AVIR be a Portfolio Killer in January?
Zacks Investment Research is releasing its prediction for AVIR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AVIR
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates
AVIR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
VRTX Q3 Earnings & Sales Trump Estimates, '24 Sales View Raised
Transplant Logistic Service Business Likely to Aid TMDX's Q3 Earnings
Other News for AVIR
Atea Pharmaceuticals engages Evercore to explore partnerships
Atea Pharmaceuticals retains financial advisor to explore partnerships
Atea Pharmaceuticals retains financial advisor to explore partnerships
Insider Sell: Franklin Berger Sells 359,606 Shares of Atea Pharmaceuticals Inc (AVIR)
Atea Pharmaceuticals Hold Rating: Promising Phase 2 Outcomes Amidst Clinical and Market Challenges